Unit of Immunotherapy of Human Tumors

Unit of Immunotherapy of Human Tumors

SEARCH FILTERS
Time filter
Source Type

Castelli C.,Unit of Immunotherapy of Human Tumors | Triebel F.,Immutep S.A. | Rivoltini L.,Unit of Immunotherapy of Human Tumors | Camisaschi C.,Unit of Immunotherapy of Human Tumors
OncoImmunology | Year: 2014

We have recently reported that lymphocyte activation gene-3 (LAG-3,CD223) mediates the alternative, IFNα-deficient activation of plasmacytoid dendritic cells (pDCs) at tumor sites. Our findings define a novel tumor-driven strategy that promotes immunosuppression by pDCs, and we have provided more detailed information regarding the immunomodulatory role of of LAG-3. The translational relevance of our results for the treatment of tumors and autoimmune diseases is discussed herein. © 2014 Taylor & Francis Group, LLC.

Loading Unit of Immunotherapy of Human Tumors collaborators
Loading Unit of Immunotherapy of Human Tumors collaborators